+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Enzymatic Wound Debridement Market Size, Share & Trends Analysis Report By End-use, By Type (Chronic Wounds and Acute Wounds), By Product (Collagenase Product, Papain Product, and Others), By Regional Outlook and Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 318 Pages
  • January 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5925331
The Global Enzymatic Wound Debridement Market size is expected to reach $1.3 billion by 2030, rising at a market growth of 6.4% CAGR during the forecast period.

In pressure ulcers, where infection is a common complication, maintaining a clean wound bed through enzymatic debridement is crucial for preventing localized and systemic infections. Therefore, the pressure ulcers segment captured $153.2 million revenue in the market in 2022. Enzymatic debridement helps reduce the risk of infection by eliminating the necrotic tissue that can serve as a breeding ground for bacteria. Pressure ulcers can be particularly challenging to manage due to the risk of further trauma to the compromised skin. Enzymatic debridement provides a minimally invasive approach, minimizing additional damage to the vulnerable tissue. Some of the factors impacting the market are advancements in enzyme formulations, growing incidence of chronic wounds and high cost of enzymatic debridement products.

Advancements in enzyme formulations often focus on enhancing the stability of enzymes. Enzymes can be sensitive to environmental conditions, and maintaining their stability is crucial for product effectiveness. Improved stability allows for a longer shelf life and better performance of enzymatic debridement products, contributing to their reliability in clinical settings. Advanced enzyme formulations often result in increased efficacy of enzymatic debridement products. Additionally, enzymatic debridement offers a cost-efficient option for managing chronic wounds, especially in outpatient settings. As healthcare systems globally strive to optimize resource utilization and shift toward providing care outside traditional hospital settings, enzymatic debridement becomes a valuable tool in the outpatient care landscape. Therefore, the increasing incidence of chronic wounds is a key driver that positively expands the market.

However, as healthcare systems worldwide faced surges in COVID-19 cases during the pandemic, there was a significant shift in priorities toward managing the pandemic. Non-essential medical procedures, including certain wound care treatments, were postponed. This delay had affected the adoption of enzymatic wound debridement in some cases, particularly for wounds that were not deemed urgent. The emphasis on infection control during the pandemic had likely influenced wound care practices, including debridement strategies. The adoption of telehealth and home-based care had surged during the pandemic. Enzymatic wound debridement had benefited from this trend with its potential for use in home care settings. Patients who were unable or hesitant to visit healthcare facilities had sought alternative solutions for wound management, leading to increased interest in home-based enzymatic debridement options. Therefore, the pandemic had a positive impact on the market.

Moreover, the upfront cost of enzymatic debridement products may be a barrier to adoption, particularly in healthcare systems with limited financial resources. Hospitals, clinics, and other healthcare establishments may be cautious about investing in these products, especially if they perceive them as expensive compared to alternative debridement methods. Healthcare providers often evaluate the cost-effectiveness of different wound care interventions. The perceived high cost of enzymatic debridement products may lead to comparisons with alternative debridement methods, such as surgical or mechanical. The economic considerations may influence decision-making in favor of more cost-efficient options. Due to the above factors, market growth will be hampered in the coming years.

End Use Outlook

By end-use, the market is categorised into hospitals, homecare, and others. In 2022, the hospitals segment generated the highest revenue share in the market. The increased prevalence of chronic lesions globally is the cause of this observation. Another factor propelling segment growth is the escalating numbers of diabetic foot ulcers and venous leg ulcers. The escalating prevalence of surgical incisions can be attributed to the surge in surgical procedures. It is also utilized to treat surgical site infections. Consequently, segment growth may be fueled by these factors throughout the forecast period.

Type Outlook

On the basis of type, the market is segmented into chronic wounds and acute wounds. The chronic wounds segment garnered a significant revenue share in the market in 2022. Pressure, diabetic foot, and venous leg ulcers are all examples of chronic lesions. Compared to other chronic wounds, the pressure ulcers segment is projected to share the rapid expansion during the forecast period. Bed sores, also called pressure ulcers, are typically the result of protracted, intense pressure on the skin. Extended hospitalization is the prevailing etiology factor for these ulcers. They are prevalent among older people and appear most frequently in bony regions, including the ankles, hips, and tailbone. Increasing geriatric populations worldwide are a significant factor in segment expansion.

Product Outlook

Based on product, the market is classified into collagenase product, papain product, and others. In 2022, the collagenase product segment witnessed the largest revenue share in the market. Enzymatic debridement products, including ointments, creams, and gels containing collagenase, remove necrotic tissue from venous leg ulcers, pressure ulcers, burn lesions, and partial-thickness burns. These products facilitate expedited wound healing and treat diabetic foot ulcers with efficacy. The products containing collagenase are readily obtainable and widely employed by medical practitioners. It is expected that the increasing incidence of pressure ulcers, ulcers in diabetic feet, and venous leg ulcers will fuel the expansion of this market segment.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region dominated the market with the maximum revenue share. An expansion in the majority of sports injuries & road accidents and the existence of several key players are factors anticipated to drive the market in North America. The US held the dominant revenue share in North America. Moreover, product launches, conferences regarding the clinical outcome, acquisitions, and collaborations in the market will likely boost market growth over the forecast period.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ConvaTec Group PLC, Smith & Nephew PLC, Molnlycke Health Care AB, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, Coloplast Group, Medline Industries, Inc., 3M Company, HARTMANN Group (Paul Hartmann AG) and MediWound Ltd.

Scope of the Study

Market Segments Covered in the Report:

By End-use
  • Hospitals
  • Homecare
  • Others
By Type
  • Chronic Wounds- Diabetic Foot Ulcers
  • Pressure Ulcers
  • Venous Leg Ulcers
  • Others
  • Acute Wounds- Burns
  • Others
By Product
  • Collagenase Product
  • Papain Product
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • ConvaTec Group PLC
  • Smith & Nephew PLC
  • Molnlycke Health Care AB
  • Integra LifeSciences Holdings Corporation
  • B.Braun Melsungen AG
  • Coloplast Group
  • Medline Industries, Inc.
  • 3M Company
  • HARTMANN Group (Paul Hartmann AG)
  • MediWound Ltd

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Enzymatic Wound Debridement Market, by End-use
1.4.2 Global Enzymatic Wound Debridement Market, by Type
1.4.3 Global Enzymatic Wound Debridement Market, by Product
1.4.4 Global Enzymatic Wound Debridement Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Global Enzymatic Wound Debridement Market by End-use
4.1 Global Hospitals Market by Region
4.2 Global Homecare Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Enzymatic Wound Debridement Market by Type
5.1 Global Chronic Wounds Market by Region
5.2 Global Enzymatic Wound Debridement Market by Chronic Wounds Type
5.2.1 Global Diabetic Foot Ulcers Market by Region
5.2.2 Global Pressure Ulcers Market by Region
5.2.3 Global Venous Leg Ulcers Market by Region
5.2.4 Global Others Market by Region
5.3 Global Acute Wounds Market by Region
5.4 Global Enzymatic Wound Debridement Market by Acute Wounds Type
5.4.1 Global Burns Market by Region
5.4.2 Global Others Market by Region
Chapter 6. Global Enzymatic Wound Debridement Market by Product
6.1 Global Collagenase Product Market by Region
6.2 Global Papain Product Market by Region
6.3 Global Others Market by Region
Chapter 7. Global Enzymatic Wound Debridement Market by Region
7.1 North America Enzymatic Wound Debridement Market
7.1.1 North America Enzymatic Wound Debridement Market by End-use
7.1.1.1 North America Hospitals Market by Country
7.1.1.2 North America Homecare Market by Country
7.1.1.3 North America Others Market by Country
7.1.2 North America Enzymatic Wound Debridement Market by Type
7.1.2.1 North America Chronic Wounds Market by Region
7.1.2.2 North America Enzymatic Wound Debridement Market by Chronic Wounds Type
7.1.2.2.1 North America Diabetic Foot Ulcers Market by Country
7.1.2.2.2 North America Pressure Ulcers Market by Country
7.1.2.2.3 North America Venous Leg Ulcers Market by Country
7.1.2.2.4 North America Others Market by Country
7.1.2.3 North America Acute Wounds Market by Region
7.1.2.4 North America Enzymatic Wound Debridement Market by Acute Wounds Type
7.1.2.4.1 North America Burns Market by Country
7.1.2.4.2 North America Others Market by Country
7.1.3 North America Enzymatic Wound Debridement Market by Product
7.1.3.1 North America Collagenase Product Market by Country
7.1.3.2 North America Papain Product Market by Country
7.1.3.3 North America Others Market by Country
7.1.4 North America Enzymatic Wound Debridement Market by Country
7.1.4.1 US Enzymatic Wound Debridement Market
7.1.4.1.1 US Enzymatic Wound Debridement Market by End-use
7.1.4.1.2 US Enzymatic Wound Debridement Market by Type
7.1.4.1.3 US Enzymatic Wound Debridement Market by Product
7.1.4.2 Canada Enzymatic Wound Debridement Market
7.1.4.2.1 Canada Enzymatic Wound Debridement Market by End-use
7.1.4.2.2 Canada Enzymatic Wound Debridement Market by Type
7.1.4.2.3 Canada Enzymatic Wound Debridement Market by Product
7.1.4.3 Mexico Enzymatic Wound Debridement Market
7.1.4.3.1 Mexico Enzymatic Wound Debridement Market by End-use
7.1.4.3.2 Mexico Enzymatic Wound Debridement Market by Type
7.1.4.3.3 Mexico Enzymatic Wound Debridement Market by Product
7.1.4.4 Rest of North America Enzymatic Wound Debridement Market
7.1.4.4.1 Rest of North America Enzymatic Wound Debridement Market by End-use
7.1.4.4.2 Rest of North America Enzymatic Wound Debridement Market by Type
7.1.4.4.3 Rest of North America Enzymatic Wound Debridement Market by Product
7.2 Europe Enzymatic Wound Debridement Market
7.2.1 Europe Enzymatic Wound Debridement Market by End-use
7.2.1.1 Europe Hospitals Market by Country
7.2.1.2 Europe Homecare Market by Country
7.2.1.3 Europe Others Market by Country
7.2.2 Europe Enzymatic Wound Debridement Market by Type
7.2.2.1 Europe Chronic Wounds Market by Country
7.2.2.2 Europe Enzymatic Wound Debridement Market by Chronic Wounds Type
7.2.2.2.1 Europe Diabetic Foot Ulcers Market by Country
7.2.2.2.2 Europe Pressure Ulcers Market by Country
7.2.2.2.3 Europe Venous Leg Ulcers Market by Country
7.2.2.2.4 Europe Others Market by Country
7.2.2.3 Europe Acute Wounds Market by Country
7.2.2.4 Europe Enzymatic Wound Debridement Market by Acute Wounds Type
7.2.2.4.1 Europe Burns Market by Country
7.2.2.4.2 Europe Others Market by Country
7.2.3 Europe Enzymatic Wound Debridement Market by Product
7.2.3.1 Europe Collagenase Product Market by Country
7.2.3.2 Europe Papain Product Market by Country
7.2.3.3 Europe Others Market by Country
7.2.4 Europe Enzymatic Wound Debridement Market by Country
7.2.4.1 Germany Enzymatic Wound Debridement Market
7.2.4.1.1 Germany Enzymatic Wound Debridement Market by End-use
7.2.4.1.2 Germany Enzymatic Wound Debridement Market by Type
7.2.4.1.3 Germany Enzymatic Wound Debridement Market by Product
7.2.4.2 UK Enzymatic Wound Debridement Market
7.2.4.2.1 UK Enzymatic Wound Debridement Market by End-use
7.2.4.2.2 UK Enzymatic Wound Debridement Market by Type
7.2.4.2.3 UK Enzymatic Wound Debridement Market by Product
7.2.4.3 France Enzymatic Wound Debridement Market
7.2.4.3.1 France Enzymatic Wound Debridement Market by End-use
7.2.4.3.2 France Enzymatic Wound Debridement Market by Type
7.2.4.3.3 France Enzymatic Wound Debridement Market by Product
7.2.4.4 Russia Enzymatic Wound Debridement Market
7.2.4.4.1 Russia Enzymatic Wound Debridement Market by End-use
7.2.4.4.2 Russia Enzymatic Wound Debridement Market by Type
7.2.4.4.3 Russia Enzymatic Wound Debridement Market by Product
7.2.4.5 Spain Enzymatic Wound Debridement Market
7.2.4.5.1 Spain Enzymatic Wound Debridement Market by End-use
7.2.4.5.2 Spain Enzymatic Wound Debridement Market by Type
7.2.4.5.3 Spain Enzymatic Wound Debridement Market by Product
7.2.4.6 Italy Enzymatic Wound Debridement Market
7.2.4.6.1 Italy Enzymatic Wound Debridement Market by End-use
7.2.4.6.2 Italy Enzymatic Wound Debridement Market by Type
7.2.4.6.3 Italy Enzymatic Wound Debridement Market by Product
7.2.4.7 Rest of Europe Enzymatic Wound Debridement Market
7.2.4.7.1 Rest of Europe Enzymatic Wound Debridement Market by End-use
7.2.4.7.2 Rest of Europe Enzymatic Wound Debridement Market by Type
7.2.4.7.3 Rest of Europe Enzymatic Wound Debridement Market by Product
7.3 Asia Pacific Enzymatic Wound Debridement Market
7.3.1 Asia Pacific Enzymatic Wound Debridement Market by End-use
7.3.1.1 Asia Pacific Hospitals Market by Country
7.3.1.2 Asia Pacific Homecare Market by Country
7.3.1.3 Asia Pacific Others Market by Country
7.3.2 Asia Pacific Enzymatic Wound Debridement Market by Type
7.3.2.1 Asia Pacific Chronic Wounds Market by Country
7.3.2.2 Asia Pacific Enzymatic Wound Debridement Market by Chronic Wounds Type
7.3.2.2.1 Asia Pacific Diabetic Foot Ulcers Market by Country
7.3.2.2.2 Asia Pacific Pressure Ulcers Market by Country
7.3.2.2.3 Asia Pacific Venous Leg Ulcers Market by Country
7.3.2.2.4 Asia Pacific Others Market by Country
7.3.2.3 Asia Pacific Acute Wounds Market by Country
7.3.2.4 Asia Pacific Enzymatic Wound Debridement Market by Acute Wounds Type
7.3.2.4.1 Asia Pacific Burns Market by Country
7.3.2.4.2 Asia Pacific Others Market by Country
7.3.3 Asia Pacific Enzymatic Wound Debridement Market by Product
7.3.3.1 Asia Pacific Collagenase Product Market by Country
7.3.3.2 Asia Pacific Papain Product Market by Country
7.3.3.3 Asia Pacific Others Market by Country
7.3.4 Asia Pacific Enzymatic Wound Debridement Market by Country
7.3.4.1 China Enzymatic Wound Debridement Market
7.3.4.1.1 China Enzymatic Wound Debridement Market by End-use
7.3.4.1.2 China Enzymatic Wound Debridement Market by Type
7.3.4.1.3 China Enzymatic Wound Debridement Market by Product
7.3.4.2 Japan Enzymatic Wound Debridement Market
7.3.4.2.1 Japan Enzymatic Wound Debridement Market by End-use
7.3.4.2.2 Japan Enzymatic Wound Debridement Market by Type
7.3.4.2.3 Japan Enzymatic Wound Debridement Market by Product
7.3.4.3 India Enzymatic Wound Debridement Market
7.3.4.3.1 India Enzymatic Wound Debridement Market by End-use
7.3.4.3.2 India Enzymatic Wound Debridement Market by Type
7.3.4.3.3 India Enzymatic Wound Debridement Market by Product
7.3.4.4 South Korea Enzymatic Wound Debridement Market
7.3.4.4.1 South Korea Enzymatic Wound Debridement Market by End-use
7.3.4.4.2 South Korea Enzymatic Wound Debridement Market by Type
7.3.4.4.3 South Korea Enzymatic Wound Debridement Market by Product
7.3.4.5 Singapore Enzymatic Wound Debridement Market
7.3.4.5.1 Singapore Enzymatic Wound Debridement Market by End-use
7.3.4.5.2 Singapore Enzymatic Wound Debridement Market by Type
7.3.4.5.3 Singapore Enzymatic Wound Debridement Market by Product
7.3.4.6 Malaysia Enzymatic Wound Debridement Market
7.3.4.6.1 Malaysia Enzymatic Wound Debridement Market by End-use
7.3.4.6.2 Malaysia Enzymatic Wound Debridement Market by Type
7.3.4.6.3 Malaysia Enzymatic Wound Debridement Market by Product
7.3.4.7 Rest of Asia Pacific Enzymatic Wound Debridement Market
7.3.4.7.1 Rest of Asia Pacific Enzymatic Wound Debridement Market by End-use
7.3.4.7.2 Rest of Asia Pacific Enzymatic Wound Debridement Market by Type
7.3.4.7.3 Rest of Asia Pacific Enzymatic Wound Debridement Market by Product
7.4 LAMEA Enzymatic Wound Debridement Market
7.4.1 LAMEA Enzymatic Wound Debridement Market by End-use
7.4.1.1 LAMEA Hospitals Market by Country
7.4.1.2 LAMEA Homecare Market by Country
7.4.1.3 LAMEA Others Market by Country
7.4.2 LAMEA Enzymatic Wound Debridement Market by Type
7.4.2.1 LAMEA Chronic Wounds Market by Country
7.4.2.2 LAMEA Enzymatic Wound Debridement Market by Chronic Wounds Type
7.4.2.2.1 LAMEA Diabetic Foot Ulcers Market by Country
7.4.2.2.2 LAMEA Pressure Ulcers Market by Country
7.4.2.2.3 LAMEA Venous Leg Ulcers Market by Country
7.4.2.2.4 LAMEA Others Market by Country
7.4.2.3 LAMEA Acute Wounds Market by Country
7.4.2.4 LAMEA Enzymatic Wound Debridement Market by Acute Wounds Type
7.4.2.4.1 LAMEA Burns Market by Country
7.4.2.4.2 LAMEA Others Market by Country
7.4.3 LAMEA Enzymatic Wound Debridement Market by Product
7.4.3.1 LAMEA Collagenase Product Market by Country
7.4.3.2 LAMEA Papain Product Market by Country
7.4.3.3 LAMEA Others Market by Country
7.4.4 LAMEA Enzymatic Wound Debridement Market by Country
7.4.4.1 Brazil Enzymatic Wound Debridement Market
7.4.4.1.1 Brazil Enzymatic Wound Debridement Market by End-use
7.4.4.1.2 Brazil Enzymatic Wound Debridement Market by Type
7.4.4.1.3 Brazil Enzymatic Wound Debridement Market by Product
7.4.4.2 Argentina Enzymatic Wound Debridement Market
7.4.4.2.1 Argentina Enzymatic Wound Debridement Market by End-use
7.4.4.2.2 Argentina Enzymatic Wound Debridement Market by Type
7.4.4.2.3 Argentina Enzymatic Wound Debridement Market by Product
7.4.4.3 UAE Enzymatic Wound Debridement Market
7.4.4.3.1 UAE Enzymatic Wound Debridement Market by End-use
7.4.4.3.2 UAE Enzymatic Wound Debridement Market by Type
7.4.4.3.3 UAE Enzymatic Wound Debridement Market by Product
7.4.4.4 Saudi Arabia Enzymatic Wound Debridement Market
7.4.4.4.1 Saudi Arabia Enzymatic Wound Debridement Market by End-use
7.4.4.4.2 Saudi Arabia Enzymatic Wound Debridement Market by Type
7.4.4.4.3 Saudi Arabia Enzymatic Wound Debridement Market by Product
7.4.4.5 South Africa Enzymatic Wound Debridement Market
7.4.4.5.1 South Africa Enzymatic Wound Debridement Market by End-use
7.4.4.5.2 South Africa Enzymatic Wound Debridement Market by Type
7.4.4.5.3 South Africa Enzymatic Wound Debridement Market by Product
7.4.4.6 Nigeria Enzymatic Wound Debridement Market
7.4.4.6.1 Nigeria Enzymatic Wound Debridement Market by End-use
7.4.4.6.2 Nigeria Enzymatic Wound Debridement Market by Type
7.4.4.6.3 Nigeria Enzymatic Wound Debridement Market by Product
7.4.4.7 Rest of LAMEA Enzymatic Wound Debridement Market
7.4.4.7.1 Rest of LAMEA Enzymatic Wound Debridement Market by End-use
7.4.4.7.2 Rest of LAMEA Enzymatic Wound Debridement Market by Type
7.4.4.7.3 Rest of LAMEA Enzymatic Wound Debridement Market by Product
Chapter 8. Company Profiles
8.1 ConvaTec Group PLC
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 SWOT Analysis
8.2 Smith & Nephew PLC
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional and Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Molnlycke Health Care AB
8.3.1 Company Overview
8.3.2 SWOT Analysis
8.4 Integra LifeSciences Holdings Corporation
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 B. Braun Melsungen AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 SWOT Analysis
8.6 Coloplast Group
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Medline Industries, LP
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Partnerships, Collaborations, and Agreements:
8.7.2.2 Approvals:
8.7.3 SWOT Analysis
8.8 3M Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 HARTMANN Group (Paul Hartmann AG)
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. MediWound Ltd
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 SWOT Analysis
Chapter 9. Winning Imperatives of Enzymatic Wound Debridement Market

Companies Mentioned

  • ConvaTec Group PLC
  • Smith & Nephew PLC
  • Molnlycke Health Care AB
  • Integra LifeSciences Holdings Corporation
  • B. Braun Melsungen AG
  • Coloplast Group
  • Medline Industries, Inc.
  • 3M Company
  • HARTMANN Group (Paul Hartmann AG)
  • MediWound Ltd

Methodology

Loading
LOADING...